Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

K. Pilatova, K. Greplova, R. Demlova, B. Bencsikova, GL. Klement, L. Zdrazilova-Dubska,

. 2013 ; 6 (-) : 42.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

With the recent addition of anti-angiogenic agents to cancer treatment, the angiogenesis regulators in platelets are gaining importance. Platelet factor 4 (PF-4/CXCL4) and Connective tissue activating peptide III (CTAP-III) are two platelet-associated chemokines that modulate tumor angiogenesis, inflammation within the tumor microenvironment, and in turn tumor growth. Here, we review the role of PF-4 and CTAP-III in the regulation of tumor angiogenesis; the results of clinical trial using recombinant PF-4 (rPF-4); and the use of PF-4 and CTAP-III as cancer biomarkers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14064142
003      
CZ-PrNML
005      
20140709122433.0
007      
ta
008      
140704s2013 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/1756-8722-6-42 $2 doi
035    __
$a (PubMed)23800319
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pilatova, Katerina $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic.
245    10
$a Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology / $c K. Pilatova, K. Greplova, R. Demlova, B. Bencsikova, GL. Klement, L. Zdrazilova-Dubska,
520    9_
$a With the recent addition of anti-angiogenic agents to cancer treatment, the angiogenesis regulators in platelets are gaining importance. Platelet factor 4 (PF-4/CXCL4) and Connective tissue activating peptide III (CTAP-III) are two platelet-associated chemokines that modulate tumor angiogenesis, inflammation within the tumor microenvironment, and in turn tumor growth. Here, we review the role of PF-4 and CTAP-III in the regulation of tumor angiogenesis; the results of clinical trial using recombinant PF-4 (rPF-4); and the use of PF-4 and CTAP-III as cancer biomarkers.
650    _2
$a zvířata $7 D000818
650    _2
$a trombocyty $x metabolismus $7 D001792
650    _2
$a lidé $7 D006801
650    _2
$a nádory $x krev $x imunologie $x patologie $7 D009369
650    _2
$a patologická angiogeneze $7 D009389
650    _2
$a peptidy $x krev $7 D010455
650    _2
$a trombocytový faktor 4 $x krev $7 D010978
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Greplova, Kristina
700    1_
$a Demlova, Regina
700    1_
$a Bencsikova, Beatrix
700    1_
$a Klement, Giannoula Lakka
700    1_
$a Zdrazilova-Dubska, Lenka
773    0_
$w MED00165458 $t Journal of hematology & oncology $x 1756-8722 $g Roč. 6, č. - (2013), s. 42
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23800319 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140709122725 $b ABA008
999    __
$a ok $b bmc $g 1031626 $s 862874
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 6 $c - $d 42 $i 1756-8722 $m Journal of hematology & oncology $n J Hematol Oncol $x MED00165458
LZP    __
$a Pubmed-20140704

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...